Abstract:GNE myopathy is a rare autosomal recessive disorder caused by mutations in the GNE gene, which is essential for the sialic acid biosynthesis pathway. Although over 200 GNE variants have been reported, some patients remain undiagnosed with only one heterozygous mutation. This study aims to analyse the entire GNE genomic region to identify novel mutations. Patients with clinically compatible GNE myopathy and mono-allelic mutations in the GNE gene were enrolled. The other GNE mutation was searched using a combination of Sanger sequencing, targeted next-generation sequencing (NGS), exon2 qPCR, and Nanopore long-read single-molecule sequencing (LRS). Verification of pseudoexons was performed by RT-PCR and sequencing of complementary DNA (cDNA) derived from frozen skeletal muscle tissue. Ten patients were enrolled, who exhibited typical symptoms, such as foot drop, walking difficulty, or distal weakness affecting both hands and lower legs. Three patients had idiopathic thrombocytopenia (ITP) and one had increased platelet count. The median age at onset was 33 years (25-44 years). A novel deep intronic variant (DIV), c.862+870C>T, was detected in nine patients from eight unrelated families. It was predicted by SpliceAI to create new splice donor sites and lead to pseudoexon inclusion. Splice-site strength scoring methods supported these predictions, indicating high probabilities of abnormal splicing. RT-PCR and sequencing of cDNA derived from muscle tissues revealed a 146 bp inserted fragment between GNE exon 5 and 6, which would result in a premature stop codon. RNA sequencing confirmed abnormal GNE splicing and expression, causing the inclusion of a pathogenic pseudoexon in GNE mRNA. This study identified a novel deep intronic disease-causing mutation in the GNE gene. It located at the allosteric region of the UDP-GlcNAc-2-epimerase (GNE) domain, which is also associated with ITP. Further research is necessary to better understand the molecular mechanisms underlying thrombocytopenia resulted from this mutation. The discovery of novel mutations in GNE, such as the deep intronic mutation activating pseudoexon inclusion, expanded the mutational spectrum of GNE myopathy. A modified genetic test algorithm covering the entire region of GNE gene will optimize the molecular diagnosis in the future. GNE myopathy is a rare autosomal recessive disorder caused by mutations in the GNE gene, which is essential for the sialic acid biosynthesis pathway. Although over 200 GNE variants have been reported, some patients remain undiagnosed with only one heterozygous mutation. This study aims to analyse the entire GNE genomic region to identify novel mutations. Patients with clinically compatible GNE myopathy and mono-allelic mutations in the GNE gene were enrolled. The other GNE mutation was searched using a combination of Sanger sequencing, targeted next-generation sequencing (NGS), exon2 qPCR, and Nanopore long-read single-molecule sequencing (LRS). Verification of pseudoexons was performed by RT-PCR and sequencing of complementary DNA (cDNA) derived from frozen skeletal muscle tissue. Ten patients were enrolled, who exhibited typical symptoms, such as foot drop, walking difficulty, or distal weakness affecting both hands and lower legs. Three patients had idiopathic thrombocytopenia (ITP) and one had increased platelet count. The median age at onset was 33 years (25-44 years). A novel deep intronic variant (DIV), c.862+870C>T, was detected in nine patients from eight unrelated families. It was predicted by SpliceAI to create new splice donor sites and lead to pseudoexon inclusion. Splice-site strength scoring methods supported these predictions, indicating high probabilities of abnormal splicing. RT-PCR and sequencing of cDNA derived from muscle tissues revealed a 146 bp inserted fragment between GNE exon 5 and 6, which would result in a premature stop codon. RNA sequencing confirmed abnormal GNE splicing and expression, causing the inclusion of a pathogenic pseudoexon in GNE mRNA. This study identified a novel deep intronic disease-causing mutation in the GNE gene. It located at the allosteric region of the UDP-GlcNAc-2-epimerase (GNE) domain, which is also associated with ITP. Further research is necessary to better understand the molecular mechanisms underlying thrombocytopenia resulted from this mutation. The discovery of novel mutations in GNE, such as the deep intronic mutation activating pseudoexon inclusion, expanded the mutational spectrum of GNE myopathy. A modified genetic test algorithm covering the entire region of GNE gene will optimize the molecular diagnosis in the future.

Estimating the Prevalence of GNE Myopathy Using Population Genetic Databases

GNE Myopathy: Genotype - Phenotype Correlation and Disease Progression in an Indian Cohort

GNE Myopathy: Etiology, Diagnosis, and Therapeutic Challenges

Global carrier frequency and predicted genetic prevalence of patients with pathogenic sequence variants in autosomal recessive genetic neuromuscular diseases

P160 A Deep Intronic Variant C.862+870c>t Correlated with GNE Myopathy and Thrombocytopenia

Mutational Spectrum and Clinical Features in 35 Unrelated Mainland Chinese Patients with GNE Myopathy

A Novel Mutation in GNE Gene: Clinical Characteristics and Bioinformatics Analysis

Novel Compound Heterozygous Mutations in a GNE Myopathy with Congenital Thrombocytopenia: A Case Report and Literature Review.

Large phenotypic diversity by genotype in patients with GNE myopathy: 10 years after the establishment of a national registry in Japan

Pseudoexon activation by deep intronic variation in GNE myopathy with thrombocytopenia

Disease Progression of GNE Myopathy and Its Relationship with Genotype: A Retrospective, Observational Study in Chinese Patients.

Novel variants and genotype-phenotype correlation in a multicentre cohort of GNE myopathy in China

Recessive GNE Mutations in Korean Nonaka Distal Myopathy Patients with or without Peripheral Neuropathy

A novel mutation alters GNE bifunctional enzyme activity and leads to familial inherited GNE diseases

A Cross-Sectional Study of Nemaline Myopathy

Understanding pathophysiology of GNE myopathy and current progress towards drug development

GNE deficiency impairs Myogenesis in C2C12 cells and cannot be rescued by ManNAc supplementation

Induced Muscle and Liver Absence of Gne in Postnatal Mice Does Not Result in Structural or Functional Muscle Impairment

Genome-first determination of the prevalence and penetrance of eight germline myeloid malignancy predisposition genes: a study of two population-based cohorts

Compromised membrane repair in muscle cells from GNE myopathy patients

The mutational profile in a South African cohort with inherited neuropathies and spastic paraplegia